p16/Ki-67 dual-staining

• Recommended in the 2015 Besthesda
• Jointly recommended by the College of American Pathologists (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP)

Detection principle

• Using immunological antigen and antibody specific combination principle, and through antibody recombination enzyme marker color system to form complex, add enzyme substrate (chromogenic agent) to make the color to treat the detection of antigen localization, qualitative.
• p16 protein is expressed in the nucleus and cytoplasm. HPV E7 protein can cause abnormal overexpression of p16 protein by inactivating pRb, so its high expression is not only a sign of the presence of virus but also an indicator of virus activity. Ki-67 protein is associated with cell proliferation and is expressed in the nucleus. The high expression of KI-67 indicated that the cells were in a period of high proliferation, and the level of the marker index was related to the grade of cervical lesions. Studies showed that there was a positive correlation between the expression intensity of Ki-67 and P16 in cervical lesion cells. In normal exfoliated cells, the expression of the two antagonizes each other. Therefore, expression of P16 and Ki-67 proteins in the same cell indicates cell cycle disorder.

Easier to read

• p16 (Nuclear + Cytoplasm) Ki-67 (Nuclear)
• Easy-to-read color identification, no dependence on morphology to find "cancerous" cells
• A positive double stain indicates that the cervical cells are diseased.

Better specificity

• P16/Ki-67 dual-staining specificity is better than HR-HPV

Higher sensitivity

• HPV-positive patients bypassed with higher sensitivity and specificity of p16/Ki-67 dual-staining cytology

Specifications:

Package: 25 tests/kit ,50 tests/kit ,100 tests/kit

Shenzhen Kisshealh Biotechnology Co., Ltd., located in the Pingshan District, Shenzhen, P.R. China. is a diagnostics company focused on the development and manufacture of IVD tests at the Point-of-Care with highly innovative proprietary technology.

We focused on the emerging markets of in vitro pathological diagnosis and immunodiagnosis. We developed, manufactured and successfully launched the in vitro immunodiagnosis platform for cancer and the POCT for infectious, genetic and chronic diseases.

<span style="color: rgb(33, 33, 33); text-transform: none; text-indent: 0px; letter-spacing: normal;" initial;"="" initial;="" 0px;="" normal;="" 255);="" 255,="" rgb(255,="" 2;="" !important;="" inline="" none;="" 600;="" 14px;="" sans-serif;="" arial,="" roboto,="" w3",="" gb="" sans="" "hiragino="" gb",="" hei",="" micro="" "wenquanyi="" sans",="" "droid="" arimo,="" freesans,="" yahei",="" "microsoft="" helvetica,="" grande",="" "lucida="" ui",="" segoe="">At Kissh we work every day to shape the future of in-vitro diagnostic testing. And our people are our best asset, the reason for our track record and our strength while we are moving forward. We live by our fundamental values and incorporate them in everything that we do. Our best asset is ‘Step Forward Every Second’